Dare Bioscience (DARE) Stock Price, News & Analysis

Company Overview

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market.

Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.

Key Stats

• Today's Range: $1.39 to $1.61
• 50-Day Range: $1.16 to $2.17
• 52-Week Range: $1.13 to $3.78
• Volume: 1.88 million shs
• Average Volume: 370,449 shs
• Market Capitalization: $21.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Dare Bioscience Stock Analysis - MarketRank™

Dare Bioscience scored higher than 50% of companies evaluated by MarketBeat, and ranked 609th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Dare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dare Bioscience has a consensus price target of $10.00, representing about 629.9% upside from its current price of $1.37.

Amount of Analyst Coverage

Dare Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dare Bioscience are expected to grow in the coming year, from ($0.97) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dare Bioscience is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dare Bioscience is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dare Bioscience has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.81% of the float of Dare Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Dare Bioscience has a short interest ratio ("days to cover") of 3.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dare Bioscience has recently increased by 39.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dare Bioscience does not currently pay a dividend.

Dividend Growth

Dare Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.78

News Sentiment

Dare Bioscience has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Dare Bioscience this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dare Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.10% of the stock of Dare Bioscience is held by insiders.

Percentage Held by Institutions

6.70% of the stock of Dare Bioscience is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/14/2026
• Investor update: 8/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:DARE
• CIK: 1401914
• Web: www.darebioscience.com
• Phone: (858) 926-7655
• Fax: 617-494-1544
• Employees: 30
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Dare Bioscience: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +604.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.40 million
• Net Margins: N/A
• Pretax Margin: -1,038.08%
• Return on Equity: N/A
• Return on Assets: -46.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.03
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $1.16 million
• Price / Sales: 18.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 7.10

Miscellaneous

• Outstanding Shares: 15,080,000
• Free Float: 14,462,000
• Market Cap: $21.41 million
• Optionable: Not Optionable
• Beta: 1.08